A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF SINGLE INTRAVENOUS DOSES OF GNX-5086 IN HEALTHY SUBJECTS

Completed

• Conditions: heart attack; 10028593; Acute myocardial infarction

• Registration Number: NL-OMON40482
• Lead Sponsor: Congenia S.r.l.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 105

Inclusion Criteria

healthy male
25 - 45 years inclusive
BMI 18.0 - 30.0 kg/m2 inclusive
non-smoker

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
Participation in another drug study within 60 days prior to randomization.
Any donation of blood(products) or significant blood loss within 60 days prior to drug administration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety<br /><br>Tolerability</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>PK</p><br>